| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| Efdamrofusp alfa | IBI-302 | Phase 3 Clinical | AP Biosciences Inc | Diabetic macular oedema; Macular Degeneration; Plaque psoriasis; Wet Macular Degeneration | 詳細 |
| NGM-621 | NGM-621 | Phase 2 Clinical | NGM Biopharmaceuticals Inc | Coronavirus Disease 2019 (COVID-19); Geographic Atrophy | 詳細 |
| RG-002-C-0106 | RG-002-C-0106; RG002C0106 | Phase 2 Clinical | Beijing Xuanjingrui Pharmaceutical Technology Co Ltd, Suzhou Xuanjing Biotechnology Co Ltd | Complement-Mediated Diseases; Glomerulonephritis, IGA; Hemolysis; Nephrotic Syndrome | 詳細 |
| APL-3007 | APL-3007 | Phase 2 Clinical | Apellis Pharmaceuticals Inc | Geographic Atrophy | 詳細 |
| SGB-9768 | SGB-9768 | Phase 2 Clinical | Suzhou Sanegene Bio Inc | C3 glomerulopathy; Glomerulonephritis; Glomerulonephritis, IGA; Glomerulonephritis, Membranoproliferative; Kidney Diseases | 詳細 |
| KRIYA-825 | KRIYA-825; VV-14295 | Phase 2 Clinical | Kriya Therapeutics Inc | Geographic Atrophy | 詳細 |
| ALXN-2030 | ALXN-2030 | Phase 2 Clinical | Alexion Pharmaceuticals Inc | Rejection of renal transplantation; Rejection of organ transplantation | 詳細 |
| LP-005 | LP-005; RX-001 | Phase 2 Clinical | Longbio Pharma (Suzhou) Co Ltd | Amyotrophic Lateral Sclerosis; C3 glomerulopathy; Carcinoma, Non-Small-Cell Lung; Complement-Mediated Diseases; Glomerulonephritis, IGA; Glomerulonephritis, Membranoproliferative; Hemoglobinuria, Paroxysmal; Kidney Diseases; Lupus Nephritis; Myasthenia Gravis; Periodontal Diseases; Peripheral Nervous System Diseases; Thrombotic Microangiopathies | 詳細 |
| ARO-C3 | ARO-C3; ARO-C-3 | Phase 2 Clinical | Arrowhead Pharmaceuticals Inc | C3 glomerulopathy; Glomerulonephritis, IGA | 詳細 |
| CG-001 | CG-001 | Phase 1 Clinical | Chengdu Konjin Co Ltd | Autoimmune Diseases; Hemoglobinuria, Paroxysmal; Myasthenia Gravis | 詳細 |
| BI-C | Phase 1 Clinical | Boehringer Ingelheim International Gmbh | Geographic Atrophy; Retinal Diseases | 詳細 | |
| Ebribafusp alfa | ADX-097 | Phase 1 Clinical | Q32 Bio Inc | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Glomerulonephritis, IGA; Kidney Diseases; Lupus Nephritis; Nephrosis, Lipoid | 詳細 |
| NM3086 | NM3086; NM-3086 | Phase 1 Clinical | NovelMed Therapeutics Inc | Hemoglobinuria, Paroxysmal | 詳細 |
| 英語名 | 研究コード | 研究開発ステージ | 会社 | オリジナル製品名 | 最初に承認をした国 | 最初の適応症 | 最初に承認を受けた会社 | 承認された日付 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|---|---|---|---|---|
| Pegcetacoplan | APL-2 | Approved | Apellis Pharmaceuticals Inc | Aspaveli, Empaveli, Syfovre | United States | Hemoglobinuria, Paroxysmal | Apellis Pharmaceuticals Inc | 2021-05-14 | Amyotrophic Lateral Sclerosis; Anemia, Hemolytic, Autoimmune; C3 glomerulopathy; Delayed Graft Function; Geographic Atrophy; Glomerulonephritis, IGA; Glomerulonephritis, Membranoproliferative; Glomerulonephritis, Membranous; Glomerulosclerosis, Focal Segmental; Hemoglobinuria, Paroxysmal; Kidney Failure, Chronic; Lupus Nephritis; Macular Degeneration; Motor Neuron Disease; Rejection of renal transplantation | 詳細 |